Variability of blood eosinophil counts with food, exercise, medications and the time of testing has the potential to affect patients’ eligibility for targeted therapy. Writing in Respirology, Professor Peter Gibson said ‘the most clinically accessible biomarker to aid in the management of asthma and COPD’ could potentially result in unexpected false negatives. He said ‘…while ...
Already a member?
Enter your email to keep reading.